HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dirk Schadendorf Selected Research

Type 6 Cyclic Nucleotide Phosphodiesterases

1/2020Retraction Note to: cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells.
3/2010cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca(2+) homeostasis in melanoma cells.
1/2008Visible light modulates the expression of cancer-retina antigens.
3/2007Photoreceptor proteins as cancer-retina antigens.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dirk Schadendorf Research Topics

Disease

395Melanoma (Melanoma, Malignant)
11/2022 - 01/2002
239Neoplasms (Cancer)
04/2022 - 01/2002
74Neoplasm Metastasis (Metastasis)
03/2022 - 03/2002
34Disease Progression
05/2021 - 06/2004
19Skin Neoplasms (Skin Cancer)
04/2022 - 01/2002
17Brain Neoplasms (Brain Tumor)
01/2022 - 02/2008
14Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2021 - 03/2007
13Merkel Cell Carcinoma
03/2022 - 01/2017
9Inflammation (Inflammations)
01/2022 - 10/2011
7Lymphatic Metastasis
01/2021 - 08/2003
7Neutropenia
01/2021 - 11/2012
7Exanthema (Rash)
01/2021 - 06/2011
6Basal Cell Carcinoma (Rodent Ulcer)
04/2022 - 08/2014
6Uveal melanoma
01/2022 - 05/2013
6Infections
01/2021 - 07/2006
6Body Weight (Weight, Body)
10/2019 - 01/2010
6Nausea
01/2018 - 06/2011
6Breast Neoplasms (Breast Cancer)
01/2018 - 11/2008
6Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
04/2008 - 04/2003
5Fever (Fevers)
01/2022 - 11/2014
5Colitis
11/2019 - 08/2015
5Hypertension (High Blood Pressure)
01/2019 - 01/2017
5Arthralgia (Joint Pain)
10/2018 - 06/2011
5Keratoacanthoma
01/2018 - 11/2010
5Fatigue
01/2018 - 06/2009
4Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021 - 12/2012
4Diarrhea
11/2017 - 06/2009

Drug/Important Bio-Agent (IBA)

60Immune Checkpoint InhibitorsIBA
03/2022 - 01/2016
52IpilimumabIBA
10/2022 - 02/2010
49AntigensIBA
11/2021 - 01/2002
47Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2022 - 02/2007
40Proteins (Proteins, Gene)FDA Link
03/2022 - 05/2002
38NivolumabIBA
10/2022 - 01/2015
38Biomarkers (Surrogate Marker)IBA
04/2022 - 08/2005
32pembrolizumabIBA
06/2022 - 01/2015
32dabrafenibIBA
01/2022 - 11/2012
30trametinibIBA
01/2022 - 07/2012
27Pharmaceutical PreparationsIBA
10/2021 - 03/2002
26VemurafenibIBA
01/2021 - 11/2010
23DNA (Deoxyribonucleic Acid)IBA
01/2022 - 11/2002
22Peptides (Polypeptides)IBA
01/2020 - 03/2002
21AntibodiesIBA
01/2022 - 03/2004
17Neoplasm Antigens (Tumor Antigens)IBA
11/2021 - 03/2002
17Dacarbazine (DIC)FDA LinkGeneric
11/2020 - 09/2005
17LigandsIBA
01/2020 - 03/2004
16EpitopesIBA
10/2021 - 03/2002
15Biological ProductsIBA
03/2022 - 07/2003
15InterferonsIBA
01/2022 - 09/2008
15Monophenol Monooxygenase (Tyrosinase)IBA
01/2022 - 03/2002
13Phosphotransferases (Kinase)IBA
05/2020 - 08/2004
12Cisplatin (Platino)FDA LinkGeneric
03/2016 - 03/2002
11binimetinibIBA
06/2022 - 03/2013
11Messenger RNA (mRNA)IBA
03/2022 - 07/2002
11L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2022 - 12/2007
11CytokinesIBA
12/2020 - 01/2002
9Monoclonal AntibodiesIBA
01/2020 - 04/2003
9Mitogen-Activated Protein KinasesIBA
05/2019 - 02/2011
8encorafenibIBA
06/2022 - 01/2018
8Differentiation AntigensIBA
01/2022 - 08/2004
7Transcription Factors (Transcription Factor)IBA
01/2022 - 02/2011
7Programmed Cell Death 1 ReceptorIBA
10/2021 - 01/2015
7MicroRNAs (MicroRNA)IBA
01/2021 - 01/2012
7VaccinesIBA
01/2017 - 03/2002
7Interferon-alpha (Interferon Alfa)IBA
01/2014 - 08/2003
6HhAntag691IBA
04/2022 - 08/2014
6B7-H1 AntigenIBA
01/2022 - 01/2017
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 02/2009
6Creatine Kinase (Creatine Phosphokinase)IBA
10/2021 - 03/2013
6Adenosine Triphosphate (ATP)IBA
02/2021 - 07/2003
6Complementary DNA (cDNA)IBA
12/2019 - 03/2003
6Telomerase (Telomerase Reverse Transcriptase)IBA
11/2018 - 01/2013
6MART-1 AntigenIBA
01/2018 - 08/2004
6EnzymesIBA
01/2017 - 01/2003
6AutoantibodiesIBA
09/2013 - 01/2007
6Etoposide (VP 16)FDA LinkGeneric
12/2006 - 03/2002
5RNA (Ribonucleic Acid)IBA
03/2022 - 01/2017
5TransducinIBA
01/2020 - 03/2007
5Microphthalmia-Associated Transcription FactorIBA
01/2019 - 11/2007
5Interferon alpha-2 (Roferon-A)FDA Link
05/2018 - 08/2003
5ParaffinIBA
01/2018 - 04/2007
5Interleukin-2 (IL2)IBA
12/2015 - 03/2002
5HLA-DR Antigens (HLA-DR)IBA
03/2014 - 06/2004
5Vindesine (Vindesin)IBA
12/2011 - 03/2002
5HLA-A*02:01 antigenIBA
10/2010 - 05/2002
4cemiplimabIBA
01/2021 - 01/2018
4CTLA-4 AntigenIBA
12/2020 - 02/2010
4Proteasome Endopeptidase Complex (Proteasome)IBA
01/2020 - 05/2002
4Type 6 Cyclic Nucleotide PhosphodiesterasesIBA
01/2020 - 03/2007
4Paclitaxel (Taxol)FDA LinkGeneric
11/2019 - 10/2003
4Sorafenib (BAY 43-9006)FDA Link
01/2018 - 06/2009
4Proto-Oncogene Proteins B-rafIBA
01/2014 - 11/2010

Therapy/Procedure

193Therapeutics
06/2022 - 03/2002
76Immunotherapy
06/2022 - 01/2002
29Drug Therapy (Chemotherapy)
01/2022 - 01/2003
15Radiotherapy
03/2022 - 05/2004
8Lymph Node Excision (Lymph Node Dissection)
01/2022 - 02/2008
7Aftercare (After-Treatment)
06/2021 - 04/2007
4Metastasectomy
03/2022 - 10/2008
4Retreatment
01/2021 - 04/2013
4Lasers (Laser)
01/2017 - 07/2003